A Soluble Dominant Negative Fibroblast Growth Factor Receptor 4 Isoform in Human MCF-7 Breast Cancer Cells

2001 ◽  
Vol 287 (1) ◽  
pp. 60-65 ◽  
Author(s):  
Shereen Ezzat ◽  
Lei Zheng ◽  
ShunJiang Yu ◽  
Sylvia L. Asa
Oncotarget ◽  
2016 ◽  
Vol 7 (36) ◽  
pp. 57633-57650 ◽  
Author(s):  
Kai Hung Tiong ◽  
Boon Shing Tan ◽  
Heng Lungh Choo ◽  
Felicia Fei-Lei Chung ◽  
Ling-Wei Hii ◽  
...  

1998 ◽  
Vol 238 (1) ◽  
pp. 177-187 ◽  
Author(s):  
Qin Wang ◽  
Paul Maloof ◽  
Huisheng Wang ◽  
Eyal Fenig ◽  
Dana Stein ◽  
...  

2009 ◽  
Vol 2 (1) ◽  
pp. 30-36 ◽  
Author(s):  
Motoki Terada ◽  
Chikara Ohnishi ◽  
Nobuhiro Ueno ◽  
Akio Shimizu ◽  
Michiyuki Kanai ◽  
...  

Cells ◽  
2018 ◽  
Vol 7 (7) ◽  
pp. 76 ◽  
Author(s):  
Navid Sobhani ◽  
Anna Ianza ◽  
Alberto D’Angelo ◽  
Giandomenico Roviello ◽  
Fabiola Giudici ◽  
...  

Breast cancer (BC) is the most common malignancy and second only to lung cancer in terms of mortality in women. Despite the incredible progress made in this field, metastatic breast cancer has a poor prognosis. In an era of personalized medicine, there is an urgent need for better knowledge of the biology leading to the disease, which can lead to the design of increasingly accurate drugs against patients’ specific molecular aberrations. Among one of the actionable targets is the fibroblast growth factor receptor (FGFR) pathway, triggered by specific ligands. The Fibroblast Growth Factor Receptors/Fibroblast Growth Factors (FGFRs/FGFs) axis offers interesting molecular targets to be pursued in clinical development. This mini-review will focus on the current knowledge of FGFR mutations, which lead to tumor formation and summarizes the state-of-the-art therapeutic strategies for targeted treatments against the FGFRs/FGFs axis in the context of BC.


2001 ◽  
Vol 194 (1) ◽  
pp. 27-34 ◽  
Author(s):  
Charles Zammit ◽  
Richard Barnard ◽  
Jennifer Gomm ◽  
Rebecca Coope ◽  
S. Shousha ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document